Emerg Infect DisEmerging Infect. DisEIDEmerging Infectious Diseases1080-60401080-6059Centers for Disease Control and Prevention24856951403675313-070010.3201/eid2006.130700Letters to the EditorLetterDistinguishing Nontuberculous Mycobacteria from Multidrug-Resistant Mycobacterium tuberculosis, ChinaNontuberculous Mycobacteria and M. tuberculosisXuKaijinBiShengJiZhongkangHuHaiyangHuFeisuZhengBeiwenWangBingRenJingjingYangShiguiDengMinChenPingRuanBingShengJifangLiLanjuanState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (K. Xu, S. Bi, Z. Ji, H. Hu, F. Hu, B. Zheng, B. Wang, J. Ren, S. Yang, M. Deng, P. Chen, B. Ruan, J. Sheng, L. Li); Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou (K. Xu, L. Li)Address for correspondence: Lanjuan Li, 79 Qingchun Rd, Hangzhou 310003, P.R. China; email: ljli@zju.edu.cn6201420610601062Keywords: tuberculosisMycobacterium tuberculosisnontuberculous Mycobacteriamultidrug-resistant Mycobacterium tuberculosisChinatuberculosis and other mycobacteriaMDR TB

To the Editor: Mycobacteria are commonly characterized by positive acid-fast staining. Most mycobacterial species belong to the nontuberculous mycobacteria (NTM), excluding species in the Mycobacterium tuberculosis complex and M. leprae. Both M. tuberculosis and NTM can induce pulmonary infection with similar symptoms and pulmonary radiographic findings (1). These similarities have led to difficulty in distinguishing these infections clinically.

As in many developing countries, the acid-fast stain is the only bacteriologic basis for diagnosing tuberculosis (TB) in primary health care institutions in China, where facilities are limited for M. tuberculosis culture, strain identification, and drug resistance detection. Thus, NTM is easily misdiagnosed as M. tuberculosis, and multidrug-resistant (MDR) TB is unable to be accurately identified. Patients with misdiagnosed TB usually are treated with the standard anti-TB regimens recommended by the Chinese government (i.e., 2HRZE/4HR [2 months of isoniazid (INH), rifampin (RIF), pyrazinmid, and ethambutol, followed by 4 months of INH and RIF 1 time daily] and 2H3R3Z3E3/4H3R3 [2 months of INH, RIF, pyrazinamide, and ethambutol followed by 4 months of INH and RIF 3 times weekly]) (2), which often results in treatment failures. Misdiagnosis is a key hurdle for effective prevention and treatment of TB (35). To evaluate the effect of misdiagnosis on TB prevention, we determined the proportion of patients with MDR TB and NTM infection in primary health care institutions in Zhejiang Province, China. Our findings would be useful for improving TB prevention and treatment.

During 2011–2012, sputum samples from 13,882 patients suspected of having TB in 8 counties in Zhejiang Province were used to culture mycobacteria. Each sample was seeded onto 2 pieces of Löwenstein-Jensen medium. A total of 1,410 samples grew mycobacteria confirmed as acid-fast bacilli by using Ziehl-Neelsen staining. The 1,410 samples were further identified by using the Mycobacteria Identification Array Kit (CapitalBio, Beijing, China). The kit contains 17 types of bacilli-specific 16S rRNA probes (i.e., M. tuberculosis complex, M. avium, M. intracellulare, M. gilvum, M. xenopi, M. smegmatis, M. aurum, M. terrae, M. gordonae, M. chelonae/abscessus, M. phlei, M. scrofulaceum, M. fortuitum, M. szulgai, M. ulcerans, M. marinum, and M. kansasii). With this method, M. tuberculosis and NTM can be distinguished, and the species of NTM can be identified (68). Of 1,410 positive strains, we identified 1,332 (94.5%) as M. tuberculosis and 78 (5.5%) as NTM. NTM strains were further identified as follows: M. intracellulare, 39 isolates; M. chelonae/abscessus, 12 isolates, M. kansasii, 13 isolates; M. avium, 3 isolates; M. fortuitum, 4 isolates; and M. scrofulaceum and M. szulgai, 1 isolate each. For 5 isolates, strain could not be classified.

We detected drug resistance of 1,332 M. tuberculosis strains using a Tuberculosis Drug Resistance Detection Array Kit (CapitalBio) (9). The mutant points for RIF resistance were identified as follows: rpoB/C531G, C531T, CG531AC, A526C, A526G, A526T, C526A, C526G, C526T, T533C, A516G, A516T, G516T, T511C, T511G, C513A, A513T, and C522T (Table). Moreover, the kit contained 5 mutant points for INH resistance, including katG (G315A, G315C, G315T, and C315) and inhA (C-15T) (Table). Of 1,332 M. tuberculosis strains, we identified 1,115 (83.7%) RIF/INH-sensitive strains, 88 (6.6%) MDR TB strains, 83 (6.2%) INH-resistant strains, and 47 (3.5%) RIF-resistant strains. Of the 1,410 positive strains, 88 (6.2%) were MDR M. tuberculosis strains.

Gene mutations of 214 drug-resistant tubercle bacilli, Zhejiang Province, China, 2011–2012
Drug
Mutant points
Mutant times
Mutant times for single site, no. (%)*
Total no. mutant times of sites related to drug resistance
IsoniazidinhA-15 (C→T)32 (18.6)172†

katG315 (G→C), (G→A)
140 (81.4)

RifampinrpoB511 (T→C)10 (7.1)140‡
rpoB513 (A→C)2 (1.4)
rpoB516 (A→T), (A→G), (G→T)19 (13.6)
rpoB526 (A→G), (A→T), (C→G), (C→T)21 (15)
rpoB531 (C→G), (C→T)84 (60.0)
rpoB533 (T→C)4 (2.9)

*No. mutant times for single site/total no. mutant times of sites related to drug resistance.
†A strain simultaneously had katG315 (G→C) and inhA-15 (C→T).
‡Five strains had the double mutation of rpoB.

The epidemiology of TB in Zhejiang Province reflects the situation in China and some developing countries (10). The clinical diagnosis and treatment of >80% TB cases in China is performed mainly by primary health care institutions. However, almost 80% of these medical institutions do not have the capability to culture M. tuberculosis, detect drug resistance, and identify strains (7). Of 1,410 strains obtained from the patients in 8 counties of Zhejiang Province, 218 (15.5%) were MDR TB, INH resistant, and RIF resistant. These affected patients could not be effectively treated with the national standard regimens. Specifically, 88 patients with MDR TB would be at risk for extensively drug-resistant TB, and 83 patients with INH-resistant TB and 47 with RIF-resistant TB would be at risk for MDR TB. In addition, we identified 78 (5.5%) NTM strains. With the acid-fast stain, these illnesses would be misidentified as TB and, in most instances, also would be reported as treatment failures. Clearly, accurate diagnosis provided by the technologies used in this study for distinguishing NTM and M. tuberculosis, Mycobacterium strain identification, and drug-resistance detection would increase the cure rate and effectively prevent TB epidemics.

For INH resistance, katG315 was a main mutant point of the M. tuberculosis strain; 140 (81.4%) of the 172 INH-resistant mutations were related to katG315. For RIF resistance, rpoB531 was a main mutant point; 84 (60.0%) of 140 RIF-resistant mutations were associated with rpoB531. Therefore, in future studies, more attention should be paid to the molecular epidemiology of katG315 and rpoB531.

In conclusion, using the techniques for M. tuberculosis culture, Mycobacterium strain identification, and drug-resistance detection is necessary. It should be urgently pursued for accurate TB diagnosis in primary health care institutions in China to improve the prevention, treatment, and control of TB.

Suggested citation for this article: Xu K, Bi S, Ji Z, Hu H, Hu F, Zheng B, et al. Distinguishing nontuberculous mycobacteria from multidrug-resistant Mycobacterium tuberculosis, China [letter]. Emerg Infect Dis [Internet]. 2014 Jun [date cited]. http://dx.doi.org/10.3201/eid2006.130700

This study was funded by the National Scientific and Technological Major Project of China (grant no. 2009ZX10004-901,2011ZX10004-901), State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and the National Natural Science Foundation of China (grant no.81070285).

ReferencesMcGrath EE, McCabe J, Anderson PB. Guidelines on the diagnosis and treatment of pulmonary non-tuberculous mycobacteria infection. Int J Clin Pract. 2008;62:194755 10.1111/j.1742-1241.2008.01891.x19166441Chinese Center for Disease Control and Prevention, Ministry of Health of the People’s Republic of China. China TB control programme implementation guide (2008) [cited 2014 Apr 16]. http://www.chinatb.org/xzf/fgznan/201207/t20120711_64166.htmZhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366:216170 10.1056/NEJMoa110878922670902Hofmann-Thiel S, Turaev L, Alnour T, Drath L, Müllerova M, Hoffmann H. Multi-centre evaluation of the speed-oligo mycobacteria assay for differentiation of Mycobacterium spp. in clinical isolates. BMC Infect Dis. 2011;11:353 10.1186/1471-2334-11-35322182531Maiga M, Siddiqui S, Diallo S, Diarra B, Traoré B, Shea YR, Failure to recognize nontuberculous mycobacteria leads to misdiagnosis of chronic pulmonary tuberculosis. PLoS ONE. 2012;7:e36902 10.1371/journal.pone.003690222615839Zhu L, Jiang G, Wang S, Wang C, Li Q, Yu H, Biochip system for rapid and accurate identification of mycobacterial species from isolates and sputum. J Clin Microbiol. 2010;48:365460 10.1128/JCM.00158-1020686082Pang Y, Zhou Y, Wang S, Tan Y, Yue J, Zhao B, Rapid molecular identification of mycobacterial species in positive culture isolates using the biochip test. Int J Tuberc Lung Dis. 2011;15:16805 10.5588/ijtld.11.006122118178Liu J, Yue J, Yan Z, Han M, Han Z, Jin L, Performance assessment of the CapitalBiol mycobacterium identification array system for identification of mycobacteria. J Clin Microbiol. 2012;50:7680 10.1128/JCM.00320-1122090408Guo Y, Zhou Y, Wang C, Zhu L, Wang S, Li Q, Rapid and accurate determination of MDR-TB in M. tuberculosis isolates and clinical sputum using a biochip system. Int J Tuberc Lung Dis. 2009;13:91420 .19555544The Office of the Fifth National TB Epidemiological Survey, Technical Guidance Group of the Fifth National TB Epidemiological Survey. The Fifth National Tuberculosis Epidemiological Survey in 2010. Chinese Journal of Antituberculosis. 2012;34:485–508 [cited 2014 Apr 16]. http://www.zgflzz.cn/CN/Y2012/V34/I8/485